Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Young Jun Oh
- Phone Number: +82-2-2228-2423
- Email: yjoh@yuhs.ac
Study Locations
-
-
-
Seoul, South Korea
- Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- scheduled for VATS lobectomy
- 40 < age < 80
- American Society of Anaesthesiologists(ASA) physical status classification I~III
- BMI > 30 kg /m2
Exclusion Criteria:
- American Society of Anaesthesiologists(ASA) physical status classification IV or more
- NYHA class III~IV
- Severe obstructive lung disease and/or restrictive lung disease patients
- patients with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure)
- arrhythmia
- pregnant women
- pulmonary edema or pulmonary arterial hypertension
- cerebrovascular disease
- unstable angina or myocardial infarction within 6 months
- patients with allergic reaction at iloprost
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
normal saline inhalation group
|
When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0).
After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1).
Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
|
|
Experimental: iloprost group
iloprost inhalation group
|
When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0).
After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1).
Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Result of arterial blood gas analysis : partial pressure of oxygen(PaO2)
Time Frame: 20 minutes after iloprost inhalation (T2)
|
20 minutes after iloprost inhalation (T2)
|
|
Result of arterial blood gas analysis : partial pressure of oxygen in the arterial blood(PaO2)/Fraction of inspired oxygen(FiO2) ratio (P/F ratio)
Time Frame: 20 minutes after iloprost inhalation (T2)
|
20 minutes after iloprost inhalation (T2)
|
|
Result of arterial blood gas analysis : Oxygen saturation in arterial blood(SaO2)
Time Frame: 20 minutes after iloprost inhalation (T2)
|
20 minutes after iloprost inhalation (T2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
deadspace
Time Frame: 20 minutes after iloprost inhalation (T2)
|
Dead space ventilation was calculated with Paco2 and end-tidal carbon dioxide (Etco2) according to the Hardman and Aitkenhead equation [1.14 × (Paco2- Etco2)/Paco2 - 0.005].
|
20 minutes after iloprost inhalation (T2)
|
|
intrapulmonary shunt
Time Frame: 20 minutes after iloprost inhalation (T2)
|
-Shunt fraction (Qs/Qt) was calculated using the following formula: Qs/Qt = (CcO2-CaO2)/(CcO2-CvO2), (1) -whereby:
|
20 minutes after iloprost inhalation (T2)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Young Jun Oh, Severance Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4-2020-0722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.